Form 4: Lexicon Pharmaceuticals SVP, Chief Medical Officer Craig B. Granowitz Reports Stock Transactions

Craig B. Granowitz, SVP and Chief Medical Officer of Lexicon Pharmaceuticals, reports the acquisition and disposition of common stock and restricted stock units on February 28, 2024.

Summary

• On February 28, 2024, Craig B. Granowitz, the SVP and Chief Medical Officer of Lexicon Pharmaceuticals, engaged in transactions involving the company's stock.
• Granowitz acquired 27,916 shares of common stock through the vesting of restricted stock units.
• He also acquired 35,790 shares of common stock through the vesting of additional restricted stock units.
• A total of 31,265 shares were disposed of to cover tax obligations at a price of $2.62 per share.
• Following these transactions, Granowitz directly owns 47,626 shares of common stock and 99,497 restricted stock units.

Sentiment

Score: 5

Explanation: This is a standard SEC filing related to stock transactions by an officer. It doesn't inherently indicate positive or negative sentiment, but rather provides factual information.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency into the trading activities of key personnel.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership by a key executive.
• The company's obligation to withhold shares for tax purposes affects the overall share count.

Key Dates